For how we live.
One found specific phenanthrene metabolites associated with fetal growth restriction and chased the mechanism. The other tested a 24-metabolite mixture against ADHD in 3,962 children and found nothing.
The MTA trial randomised 579 children and found medication management clearly superior short-term. Its own long-term follow-up found the treatment groups no longer differed by 6 to 8 years.
The committee that decides what Israel's national insurance covers added new cancer and depression drugs to the 2026 list — and turned down an early Alzheimer's treatment because of what it would have cost.
The paper is a literature review, not a new trial — it synthesizes existing research rather than testing anything new. The authors argue return-to-play protocols may need to treat ADHD as a distinct variable.
A meta-analysis of 23 blinded studies found no effect on any of 14 behavioural and cognitive measures. A separate trial fed children extreme doses and found nothing. The belief survives anyway.
Simtriyo works on a different neurotransmitter pathway than existing stimulants. But its own manufacturer classifies it as a CNS stimulant, so a scheduling review stands before pharmacy shelves.
A single-author analysis of Global Burden of Disease estimates finds the region's neurodevelopmental picture split in two — and argues the flat autism curve reflects diagnostic capacity, not risk.
A cross-sectional analysis of NICE evaluations found 78 supporting studies behind 30 technologies — and consistent holes in comparators, cost of delivery and adverse-event reporting.
The barriers parents named most often were cost and the absence of any nearby service — not stigma, which the field has spent years treating as the main obstacle.
A population study covering all 15 million residents of Ontario found the rate of new ADHD medication prescriptions accelerated sharply after 2019 — and shifted decisively toward adults.